IPP Bureau
Lupin achieves S&P Global ESG score of 91
By IPP Bureau - November 14, 2025
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg
By IPP Bureau - November 14, 2025
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Merck KGaA Q3 2025 net sales remains flat amid geopolitical uncertainty
By IPP Bureau - November 14, 2025
Terumo BCT and Santersus partner to advance blood purification therapy for sepsis
By IPP Bureau - November 14, 2025
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Hormone therapy for menopause gets green light from FDA
By IPP Bureau - November 14, 2025
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Daiichi Sankyo launches first-in-human trial of innovative cancer therapy
By IPP Bureau - November 14, 2025
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Novartis opens radioligand therapy facility in Carlsbad, US
By IPP Bureau - November 14, 2025
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
UK MHRA finds gut microbiome research unreliable across labs
By IPP Bureau - November 14, 2025
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Kaiser Permanente’s study highlights power of genetics in preventing heart disease
By IPP Bureau - November 14, 2025
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
Roche reports breakthrough phase III results for investigational multiple sclerosis drug
By IPP Bureau - November 14, 2025
Fenebrutinib targets cells in the immune system known as B cells and microglia
LANXESS set to showcase cutting-edge infection control solutions
By IPP Bureau - November 14, 2025
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Diabetes on the rise: Over 50% of Indians show high blood sugar, reveals report
By IPP Bureau - November 14, 2025
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
Enzymit and Cosun chart breakthrough in cell-free hyaluronic acid production
By IPP Bureau - November 14, 2025
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD
By IPP Bureau - November 14, 2025
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
SpyGlass Pharma reports promising clinical trial results for glaucoma therapy
By IPP Bureau - November 14, 2025
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
